Role of altered metabolism in dideoxynucleoside pharmacokinetics: Studies of 2'-β-Fluoro-2',3'-dideoxyinosine and 2'-β-Fluoro-2',3'- dideoxyadenosine in rats

Drug Metabolism and Disposition

Volumn 24, Issue 10, 1996, Pages 1155-1161

  Singhal, Dharmendra ^a   Morgan, Michael E ^a   Anderson, Bradley D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' BETA FLUORO 2',3' DIDEOXYINOSINE; 2',3' DIDEOXY 2' FLUOROADENOSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; PENTOSTATIN; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ADENOSINE DEAMINASE; ANIMALS; ANTI-HIV AGENTS; DIDANOSINE; DIDEOXYADENOSINE; ENZYME INHIBITORS; MALE; PENTOSTATIN; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

ADA; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029858261     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. N. Clumeck: Current use of anti-HIV drugs in AIDS. J. Amimicrob. Chemother. 32, 133-138 (1993).
2. H. Mitsuya, R. Yarchoan, and S. Broder: Molecular targets for AIDS therapy. Science (Wash. DC) 249, 1533-1544 (1990).
3. H. Mitsuya, R. Yarchoan, S. Kageyama, and S. Broder: Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 5, 2369-2381 (1991).
4. D. A. Cooney, G. Ahluwalia, H. Mitsuya, A. Fridland, M. Johnson, Z. Hao, M. Dalal, J. Balzarini, S. Broder, and D. G. Johns: Initial studies on the cellular pharmacology of 2′,3′-dideoxyadenosine, an inhibitor of HTLV-III. infectivity. Biochem. Pharmacol. 36, 1765-1768 (1987).
5. G. Ahluwalia, D. A. Cooney, H. Mitsuya, A. Fridland, K. P. Flora, Z. Hao, M. Dalal, S. Broder, and D. G. Johns: Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36, 3797-3800 (1987).
6. R. E. Parks, Jr., G. W. Crabtree, C. M. Kong, R. P. Agarwal, K. C. Agarwal, and E. M. Scholar: Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes. Ann. N.Y. Acad. Sci. 255, 412-434 (1975).
7. G. Mistry and G. I. Drummond: Adenosine metabolism in microvessels from heart and brain. J. Mol. Cell Cardiol. 18, 13-22 (1986).
8. M. G. Wientjes, M. E. Placke, M. J. Chang, J. G. Page, W. M. Kluwe, and J. E. Tomaszewski: Pharmacokinetics of 2′,3′-dideoxyadenosine in dogs. Invest. New Drugs 9, 159-168 (1991).
9. B. D. Anderson, M. B. Wygant, T.-X. Xiang, W. A. Waugh, and V. Stella: Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int. J. Pharmacol. 45, 27-37 (1988).
10. N. R. Hartman, R. Yarchoan, J. M. Pluda, R. V. Thomas, K. M. Wyvill, K. P. Flora, S. Broder, and D. G. Johns: Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin. Pharmacol. Ther. 50, 278-285 (1991).
11. J. W. Russell and L. J. Klunk: Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem. Pharmacol. 38, 1385-1388 (1989).
12. C. L. Zielke and C. H. Suelter: Purine, purine nucleoside, and purine nucleotide aminohydrolases. In "The Enzymes" (P. D. Boyer, ed.), vol. 4, pp. 47-78. Academic Press, London, 1971.
13. T. G. Brady and C. I. O'Donovan: A study of the tissue distribution of adenosine deaminase in six mammal species. Comp. Biochem. Physiol. 14, 101-120 (1965).
14. V. E. Marquez, C. K.-H. Tseng, J. A. Kelley, H. Mitsuya, S. Broder, J. S. Roth, and J. S. Driscoll: 2′,3′-Dideoxy-2′-fluoro-ara-A: an acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36, 2719-2722 (1987).
15. V. E. Marquez, C. K.-H. Tseng, H. Mitsuya, S. Aoki, J. A. Kelley, H. Ford, Jr., J. S. Roth, S. Broder. D. G. Johns, and J. S. Driscoll: Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J. Med. Chem. 33, 978-985 (1990).
16. R. Masood, G. S. Ahluwalia, D. A. Cooney, A. Fridland, V. E. Marquez, J. S. Driscoll, Z. Hao, H. Mitsuya, C. F. Perno, S. Broder, and D. G. Johns.: 2′-Fluoro-2′,3′-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2′,3′-dideoxyadenosine. Mol. Pharmacol. 37, 590-596 (1990).
17. J. J. Barchi, Jr., V. E. Marquez, J. S. Driscoll, H. Ford, Jr., H. Mitsuya, T. Shirasaka, S. Aoki, and J. A. Kelley: Potential anti-AIDS drugs: lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 34, 1647-1655 (1991).
18. R. E. Kimura, T. R. LaPine, and W. M. Gooch III: Portal venous and aortic glucose and lactale changes in a chronically catheterized rat. Pediatr. Res. 23, 235-240 (1988).
19. M. Gibaldi and D. Perrier: "Pharmacokinetics," pp. 75-81. Marcel Dekker, New York, 1982.
20. B. L. Hoesterey, R. E. Galinsky, and B. D. Anderson: Dose dependence in the plasma pharmacokinetics and uptake kinetics of 2′,3′-dideoxyinosine (ddI) into brain and CSF of rats. Drug Metab. Dispos. 19, 907-912 (1991).
21. M. G. Wientjes, E. Mukherji, and J. L.-S. Au: Nonlinear disposition of intravenous 2′,3′-dideoxyinosine in rats. Pharm. Res. 9, 1070-1075 (1992).
22. W. R. McConnell, R. L. Furner, and D. L. Hill: Pharmacokinetics of 2′-deoxycoformycin in normal and L1210 leukemic mice. Drug Metab. Dispos. 7, 11-13 (1979).
23. J. D. Geiger, J. L. Lewis, C. J. MacIntyre, and J. I. Nagy: Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase in the rat. Neuropharmacology 26, 1383-1387 (1987).
24. D. A. Cooney, M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Baizarini, S. Broder, and D. G. Johns: Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35, 2065-2068 (1986).
25. M. G. Wientjes and J. L.-S. Au: Pharmacokinetics of oral 2′,3′-dideoxyinosine in rats. Pharm. Res. 9, 822-825 (1992).
26. B. D. Anderson, R. E. Galinsky, D. C. Baker, S.-C. Chi, B. L. Hoesterey, M. E. Morgan, K. Murakami, and H. Mitsuya: Approaches toward the optimization of CNS uptake of anti-AIDS agents. J. Control. Rel. 19, 219-230 (1992).
27. M. E. Morgan, S.-C. Chi, K. Murakami, H. Mitsuya, and B. D. Anderson: Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 36, 2156-2165 (1992).
28. T. Shirasaka, K. Murakami, H. Ford, J. A. Kelly, H. Yoshioka, E. Kojima, S. Aoki, S. Broder, and H. Mitsuya: Lipophilic halogenated congeners of 2′,3′-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 87, 9426-9430 (1990).
29. G. S. Ahluwalia, D. A. Cooney, T. Shirasaka, H. Mitsuya, J. S. Driscoll, and D. G. Johns: Enhancement by 2′-deoxycoformycin of the 5′-phosphorylation and anti-human immunodeficiency virus activity of 2′,3′-dideoxyadenosine and 2′-β-fluoro-2′,3′-dideoxyadenosine. Mol. Pharmacol. 46, 1002-1008 (1994).
30. R. Padua, J. D. Geiger, S. Dambock, and J. I. Nagy: 2′-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery. J. Neurochem. 54, 1169-1178 (1990).
31. R. N. Brogden and E. M. Sorkin: Pentostatin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 46, 652-677 (1993).
32. W. D. Klohs and A. J. Kraker: Pentostatin: future directions. Pharmacol. Rev. 44, 459-477 (1992).
33. E. H. Kraut, B. A. Bouroncle, and M. R. Grever: Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol. 7, 168-172 (1989).